We had such patients in the hospital.

We wrote the article "Basic predictive risk factors for cytokine storms in COVID-19 patients".

The treatment of COVID-19 patients included antibacterial and antiviral drugs, prevention of hypercoagulability and Disseminated Intravascular Coagulation, symptoms-related treatment, and oxygen therapy. To prevent or treat the cytokine storm depending on the disease severity, in group 2 standard treatment was supplemented with convalescent plasma therapy, anticytokine drugs: interleukine-6 (IL-6) inhibitors (tocilizumab, olokizumab, levilimab), IL-1 inhibitors (canakinumab, RH104), JAK-inhibitors (tofacitinib, ruxolitinib, baricitinib), Bcr–Abl tyrosine kinase inhibitor (radotinib) – and glucocorticoids for some cases. Respiratory therapy, modified antibacterial therapy, extracorporeal membrane oxygenation, sepsis and septic shock treatment (extracorporeal detoxication and blood purification, etc.) were performed in a stepwise fashion according to indications

Thanks a lot for this complete response!!!!!!!!!

YOUR EXPERIENCE ABOUT tocilizumab, olokizumab, levilimab IN PATIENTS WITH SEVERE DISEASES? INITIAL DOSE? AFTER INITIAL DOSE?